Gilead Sciences, Inc. [NASDAQ: GILD] closed the trading session at $71.58. The company report on February 13, 2024 at 8:30 AM that Gilead Sets Sights on Hepatitis C Elimination As It Marks 10 Years of Curative Therapies.
Long-time liver specialist Carrie Frenette says she won’t ever forget the people she treated for hepatitis C (HCV) before 2013 – the year that the Food and Drug Administration (FDA) approved a Gilead medicine. The medicine was the first curative therapy for HCV.
“More than a decade ago, treatment options were not only limited but were often associated with harsh side effects,” says Carrie, who after two decades of being a clinician now works at Gilead as Executive Director, Global Medical Affairs, Liver Diseases.
The stocks have a year to date performance of -11.64 percent and weekly performance of -2.84 percent. The stock has been moved at -6.43 percent over the last six months. The stock has performed -17.15 percent around the most recent 30 days and changed -4.61 percent over the most recent 3-months.
If compared to the average trading volume of 7.17M shares, GILD reached to a volume of 12463211 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Gilead Sciences, Inc. [GILD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GILD shares is $87.11 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GILD stock is a recommendation set at 2.13. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Deutsche Bank have made an estimate for Gilead Sciences, Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on November 09, 2023.
The Average True Range (ATR) for Gilead Sciences, Inc. is set at 1.64, with the Price to Sales ratio for GILD stock in the period of the last 12 months amounting to 3.30. The Price to Book ratio for the last quarter was 3.92, with the Price to Cash per share for the same quarter was set at 6.76. Price to Free Cash Flow for GILD in the course of the last twelve months was 11.36 with Quick ratio for the last quarter at 1.16.
GILD stock trade performance evaluation
Gilead Sciences, Inc. [GILD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.84. With this latest performance, GILD shares dropped by -17.15% in over the last four-week period, additionally sinking by -6.43% over the last 6 months – not to mention a drop of -15.84% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GILD stock in for the last two-week period is set at 27.86, with the RSI for the last a single of trading hit 22.33, and the three-weeks RSI is set at 32.75 for Gilead Sciences, Inc. [GILD]. The present Moving Average for the last 50 days of trading for this stock 79.97, while it was recorded at 73.19 for the last single week of trading, and 77.89 for the last 200 days.
Gilead Sciences, Inc. [GILD]: An insightful look at the core fundamentals
Gilead Sciences, Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.16 and a Current Ratio set at 1.46.
Earnings per share (EPS) analysis for Gilead Sciences, Inc. [GILD] stock
With the latest financial reports released by the company, Gilead Sciences, Inc. posted 1.37/share EPS, while the average EPS was predicted by analysts to be reported at 1.54/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -11.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GILD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Gilead Sciences, Inc. go to 5.13%.
Gilead Sciences, Inc. [GILD]: Institutional Ownership
The top three institutional holders of GILD stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in GILD stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in GILD stock with ownership which is approximately 5.8325%.
